期刊文献+

坎地沙坦对小鼠肝癌移植瘤及新生血管生成的抑制作用 被引量:2

The inhibitory effect of candesartan on growth and angiogenesis of mice bearing hepatocellular carcinoma xenograft
下载PDF
导出
摘要 目的 探讨血管紧张素Ⅱ1型受体拮抗剂坎地沙坦对小鼠肝癌移植瘤生长及血管生成的影响.方法 建立肝癌H22细胞小鼠移植瘤模型.将48只小鼠随机分为生理盐水组(0.2ml d1~d8)、低剂量坎地沙坦组(2mg/kg,0.2ml d1~ds)、高剂量坎地沙坦组(20mg/kg,0.2ml d1~d8)和氟尿嘧啶组(25 mg/kg,0.2ml d1~d6),每组12只.第9天处死小鼠取瘤组织,测瘤重,计算抑瘤率;免疫组化法检测移植瘤组织内血管内皮生长因子(VEGF)和CD34表达,测定微血管密度(MVD).另取40只小鼠以相同条件进行平行实验,每组10只,观察小鼠的生存时间.结果 高剂量坎地沙坦组及氟尿嘧啶组的抑瘤率分别为35.3%和50.6%,均高于低剂量坎地沙坦组的20.7%,差异有统计学意义(P<0.05);与生理盐水组相比,低剂量(5.083±1.240)与高剂量坎地沙坦组(4.083±1.165) VEGF分值均显著降低(P<0.05),且高剂量组降低更明显(P<0.05);与生理盐水组相比,低剂量(20.633±2.171)与高剂量(17.150±2.713)坎地沙坦组MVD均显著降低(P<0.01),且高剂量组降低更明显(P<0.05);高剂量坎地沙坦组及氟尿嘧啶组小鼠的生命延长率分别为39.5%和30.6%,均高于低剂量坎地沙坦组的20.4% (P <0.05).结论 坎地沙坦可抑制小鼠肝癌移植瘤的生长,其机制可能与抑制肿瘤新生血管生成有关. Objective To investigate the influence of angiotensin Ⅱ type 1 receptor blocker candesartan on growth and angiogenesis of mice bearing human hepatocellular carcinoma xenograft.Methods Fourty-eight mice bearing H22 hepatocellular carcinoma xenograft were established and randomly divided into normal saline group,low-dose candesartan group(2mg/kg),high-dose candesartan group (20mg/kg)and flurouracil group(25mg/kg)with 12 in each group.Nine days after administration,the mice were sacrificed,and the weight of transplanted tumors was measured to calculate the tumor inhibitory rate.The immunohistochemical technology was adopted to detect the expressions of vascular endothelial growth factor(VEGF) and CD34 to calculate microvessel density(MVD).The same test was applied to 40 mice to observe the survival time and calculate the life extension rate.Results The tumor inhibition rates in high-dose candesartan group(35.3%) and fluorouracil group(50.6%) were higher than 20.7% in low-dose candesartan group(P <0.05).Compared with the normal saline group,significant reduction of VEGF expression was observed in low-dose (5.083 ± 1.240) and high-dose candesartan(4.083 ± 1.165) with significance(P < 0.05).VEGF score in high-dose candesartan was lower than that in low-dose candesartan(P <0.05).Compared with the normal saline group,the MVD in low-dose(20.633 ±2.171) and high-dose candesartan groups (17.150 ± 2.713) were significantly reduced(P < 0.01).Compared with low-dose candesartan group,the MVD in high-dose candesartan group were significantly reduced(P <0.05).The life extension rates in low-dose candesartan group(20.4%) was lower than 39.5% in high-dose candesartan group and 30.6% in fluorouracil group (P < 0.05).Conclusion Candesartan is effective in inhibiting the growth of hepatocellular carcinoma xenograft,and the possible mechanism may be related to the inhibition of angiogenesis.
出处 《临床肿瘤学杂志》 CAS 2013年第10期869-873,共5页 Chinese Clinical Oncology
关键词 血管紧张素Ⅱ1型受体 坎地沙坦 肝癌 新生血管生成 Angiotensin-Ⅱ type 1 receptor(AT1 R) Candesartan Hepatocellular carcinoma Angiogenesis
  • 相关文献

参考文献16

  • 1Fujimoto Y,Sasaki T,Tsuchida A,et al.Angiotensin Ⅱ type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin Ⅱ type 1 receptor antagonist[J].FEBS Left,2001,495(3):197-200.
  • 2Du N,Feng J,Hu LJ,et al.Angiotensin Ⅱ receptor type 1 blockers suppress the cell proliferation effects of angiotensin Ⅱ in breast cancer cells by inhibiting AT1R signaling[J].Oncol Rep,2012,27(6):1893-1903.
  • 3Uemura H,Ishiguro H,Nakaigawa N,et al.Angiotensin Ⅱ receptor blocker shows antiproliferative activity in prostate cancer cells:A possibility of tyrosine kinase inhibitor of growth factor[J].Mol Cancer Ther,2003,2 (11):1139-1147.
  • 4刘佳,王笑云,徐亚光,刘艳春,卞帅博,赵鲁米,赵秀芬,钱军,邢昌赢.氟伐他汀联合氯沙坦对血管紧张素Ⅱ诱导的人足细胞血管内皮生长因子表达的影响及机制研究[J].中华肾脏病杂志,2012,28(9):710-714. 被引量:4
  • 5Chakra M,Pujol JL,Lamy PJ,et al.Circulating serum vascular endothelial growth factor is not a prognostic factor of non-sm all cell lung cancer[J].J Thorac Oncol,2008,3 (10):1119-1126.
  • 6H anrahan EO,Ryan AJ,Mann H,et al.Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-smallcell lung cancer[J].ClinCan Res,2009,15 (10):3600-3609.
  • 7刘臻臻,罗琪.肿瘤血管靶向治疗策略的新进展[J].世界华人消化杂志,2010,18(27):2889-2893. 被引量:11
  • 8狄茂军,王卫星,兰明银,江斌,李恒,易建华.血管紧张素ⅡⅠ型受体在人肝细胞癌中的表达及意义[J].武汉大学学报(医学版),2005,26(2):235-237. 被引量:4
  • 9Suganuma T,Ino K,Shibata K,et al.Functional expression of the angiotensin Ⅱ typel receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion,angiogenesis,and peritoneal dissemination[J].Clin Cancer Res,2005,11 (7):2686-2694.
  • 10Wilop S,von Hobe S,Crysandt M,et al.Impact of angiotensin Ⅰ converting enzyme inhibitors and angiotensin Ⅱ type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy[J].J Cancer Res Clin Oncol,2009,135 (10):1429-1435.

二级参考文献30

共引文献18

同被引文献22

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部